Treats hyperkalemia. ANDA 87859, held by Cmp Pharma Inc. Sodium Polystyrene Sulfonate.
As of Nov 16, 2026, ANDA 87859 (Sps), held by Cmp Pharma Inc, was first approved by FDA on Dec 8, 1982, with 12 approved supplements and 0 published complete response letters.
INDICATION AND USAGE SPS Suspension is indicated for the treatment of hyperkalemia.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 8, 1982 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Sps15GM/60ML · suspension;oral, rectal | Sodium Polystyrene Sulfonate | RxReference drug |
| Nov 5, 2026 | Supplement 29Labeling · Standard review | Approved | None posted |
| Jun 24, 2011 | Supplement 25Labeling | Approved | None posted |
| Mar 3, 2011 | Supplement 24Labeling | Approved | None posted |
| Mar 3, 2011 | Supplement 23Labeling | Approved | None posted |
| Mar 18, 2004 | Supplement 20Labeling | Approved | None posted |
| Nov 30, 2000 | Supplement 18Manufacturing | Approved | None posted |
| Dec 12, 1991 | Supplement 13Labeling | Approved | None posted |
| May 31, 1991 | Supplement 14Manufacturing | Approved | None posted |
| Jul 18, 1989 | Supplement 12Manufacturing | Approved | None posted |
| Jul 16, 1987 | Supplement 10Manufacturing | Approved | None posted |
| Dec 12, 1985 | Supplement 3Manufacturing | Approved | None posted |
| Apr 27, 1983 | Supplement 1Manufacturing | Approved | None posted |
| Dec 8, 1982 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters